Tryptophan-Derived Uremic Toxins and Thrombosis in Chronic Kidney Disease - PubMed (original) (raw)

Review

Tryptophan-Derived Uremic Toxins and Thrombosis in Chronic Kidney Disease

Tawfik Addi et al. Toxins (Basel). 2018.

Abstract

Patients with chronic kidney disease (CKD) display an elevated risk of thrombosis. Thrombosis occurs in cardiovascular events, such as venous thromboembolism, stroke, and acute coronary syndrome, and is a cause of hemodialysis vascular access dysfunction. CKD leads to the accumulation of uremic toxins, which exerts toxic effects on blood and the vessel wall. Some uremic toxins result from tryptophan metabolization in the gut through the indolic and the kynurenine pathways. An increasing number of studies are highlighting the link between such uremic toxins and thrombosis in CKD. In this review, we describe the thrombotic mechanisms induced by tryptophan-derived uremic toxins (TDUT). These mechanisms include an increase in plasma levels of procoagulant factors, induction of platelet hyperactivity, induction of endothelial dysfunction/ impairment of endothelial healing, decrease in nitric oxide (NO) bioavailability, and production of procoagulant microparticles. We focus on one important prothrombotic mechanism: The induction of tissue factor (TF), the initiator of the extrinsic pathway of the blood coagulation. This induction occurs via a new pathway, dependent on the transcription factor Aryl hydrocarbon receptor (AhR), the receptor of TDUT in cells. A better understanding of the prothrombotic mechanisms of uremic toxins could help to find novel therapeutic targets to prevent thrombosis in CKD.

Keywords: chronic kidney disease; thrombosis; tryptophan; uremic toxins.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1

Figure 1

Mechanisms of tryptophan-derived uremic toxins promoting thrombosis. Tryptophan-derived uremic toxins promote thrombosis by inducing platelet hyperactivity, endothelial dysfunction, production of endothelial and platelet microparticles, and TF expression on monocytes, vSMC, and EC. TF induction is mediated by AhR activation. A decrease in NO bioavailability and an induction of ROS in platelets and endothelial cells participate in the thrombotic effects of tryptophan-derived uremic toxins. AhR: Aryl hydrocarbon Receptor; TF: Tissue Factor; EC: Endothelial cells, vSMC: Vascular smooth muscle cells; ROS: Reactive oxygen species; NO: Nitric Oxide.

Similar articles

Cited by

References

    1. Levin A., Stevens P., Bilous R.W., Coresh J., De Francisco A.L., De Jong P.E., Griffi K.E., Hemmelgarn B.R., Isek K., Lamb E.J., et al. KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. Chapter 1: Definition and classification of CKD. Kidney Int. Suppl. 2013;3:19–62. doi: 10.1038/kisup.2012.64. - DOI
    1. Stevens P.E., Levin A. Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members Evaluation and management of chronic kidney disease: Synopsis of the kidney disease: Improving global outcomes 2012 clinical practice guideline. Ann. Intern. Med. 2013;158:825–830. doi: 10.7326/0003-4819-158-11-201306040-00007. - DOI - PubMed
    1. Coresh J., Turin T.C., Matsushita K., Sang Y., Ballew S.H., Appel L.J., Arima H., Chadban S.J., Cirillo M., Djurdjev O., et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 2014;311:2518–2531. doi: 10.1001/jama.2014.6634. - DOI - PMC - PubMed
    1. Di Angelantonio E., Danesh J., Eiriksdottir G., Gudnason V. Renal function and risk of coronary heart disease in general populations: New prospective study and systematic review. PLoS Med. 2007;4:e270. doi: 10.1371/journal.pmed.0040270. - DOI - PMC - PubMed
    1. Herzog C.A., Asinger R.W., Berger A.K., Charytan D.M., Díez J., Hart R.G., Eckardt K.-U., Kasiske B.L., McCullough P.A., Passman R.S., et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO) Kidney Int. 2011;80:572–586. doi: 10.1038/ki.2011.223. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources